Prokinetics and fundic relaxants in upper functional GI disorders

Current Opinion in Pharmacology

Volumn 8, Issue 6, 2008, Pages 690-696

  Tack, Jan ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACOTIAMIDE; ALEMCINAL; ATI 7505; BUSPIRONE; CISAPRIDE; CLEBOPRIDE; CLONIDINE; DIGESTIVE TRACT AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; ITOPRIDE; MITEMCINAL; MOSAPRIDE; MUSCARINIC M1 RECEPTOR ANTAGONIST; MUSCARINIC M2 RECEPTOR ANTAGONIST; MUSCLE RELAXANT AGENT; N [2 (DIISOPROPYLAMINO)ETHYL] 2 (2 HYDROXY 4,5 DIMETHOXYBENZAMIDO) 4 THIAZOLECARBOXAMIDE; NITRIC ACID DERIVATIVE; PLACEBO; PROKINETIC AGENT; PRUCALOPRIDE; R 137696; RENZAPRIDE; SEROTONIN 1A AGONIST; SEROTONIN 4 AGONIST; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; TD 5108; TEGASEROD; TZP 101; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPEPSIA; GASTRIC DYSMOTILITY; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HUMAN; INTESTINE TRANSIT TIME; MUSCLE EXCITATION; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE RELAXATION; STOMACH EMPTYING; STOMACH FUNDUS; STOMACH MUSCLE; STOMACH PARESIS; SYMPTOM; TREATMENT OUTCOME; UPPER GASTROINTESTINAL TRACT;

ANIMALS; GASTRIC FUNDUS; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; HUMANS; MODELS, BIOLOGICAL; MUSCLE RELAXATION; MUSCLE, SMOOTH; UPPER GASTROINTESTINAL TRACT;

EID: 55649095491     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2008.09.009     Document Type: Review

References (73)

1. Tack J. Gastric motor disorders. Best Pract Res Clin Gastroenterol 21 (2007) 633-644
2. Vantrappen G., Janssens J., Hellemans J., and Ghoos Y. The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. J Clin Invest 59 (1977) 1158-1166
3. Tack J., Piessevaux H., Coulie B., Caenepeel P., and Janssens J. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 115 (1998) 1346-1352
4. Abell T.L., Bernstein R.K., Cutts T., Farrugia G., Forster J., Hasler W.L., McCallum R.W., Olden K.W., Parkman H.P., Parrish C.R., et al. Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil 18 (2006) 263-283
5. Vecht J., Masclee A.A., and Lamers C.B. The dumping syndrome. Current insights into pathophysiology, diagnosis and treatment. Scand J Gastroenterol Suppl 223 (1997) 21-27
6. Tack J., Talley N.J., Camilleri M., Holtmann G., Hu P., Malagelada J.R., and Stanghellini V. Functional gastroduodenal disorders. Gastroenterology 130 (2006) 1466-1479. Rome 3 consensus definitions of functional dyspepsia and other functional disorders of the upper gastrointestinal tract.
7. Tack J., Bisschops R., and Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 127 (2004) 1239-1255
8. Kindt S., and Tack J. Impaired gastric accommodation and its role in dyspepsia. Gut 55 (2006) 1685-1691
9. Delgado-Aros S., Camilleri M., Cremonini F., Ferber I., Stephens D., and Burton D.D. Contributions of gastric volumes and gastric emptying to meal size and postmeal symptoms in functional dyspepsia. Gastroenterology 127 (2004) 1685-1694
10. Karamanolis G., Caenepeel P., Arts J., and Tack J. Determinants of symptom pattern in idiopathic severely delayed gastric emptying: gastric emptying rate or proximal stomach dysfunction?. Gut 56 (2007) 29-36
11. Moayyedi P., Soo S., Deeks J., Delaney B., Innes M., and Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 18 (2006) CD001960
12. Karamanolis G., and Tack J. Promotility medications-now and in the future. Dig Dis 24 (2006) 297-307
13. Talley N.J., Verlinden M., Snape W., Beker J.A., Ducrotte P., Dettmer A., Brinkhoff H., Eaker E., Ohning G., Miner P.B., et al. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 14 (2000) 1653-1661
14. 4 agonists and their respective pharmacological properties.
15. Beattie D.T., Smith J.A., Marquess D., Vickery R.G., Armstrong S.R., Pulido-Rios T., McCullough J.L., Sandlund C., Richardson C., Mai N., and Humphrey P.P. The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2b receptor antagonist in vitro and in vivo. Br J Pharmacol 143 (2004) 549-560
16. Tack J., Müller-Lissner S., Bytzer P., Corinaldesi R., Chang L., Viegas A., Schnekenbuehl S., Dunger-Baldauf C., and Rueegg P. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation (IBS-C). Gut 54 (2005) 1707-1713
17. Kamm M.A., Müller-Lissner S., Talley N.J., Tack J., Boeckxstaens G., Minushkin O.N., Kalinin A., Dzieniszewski J., Haeck P., Fordham F., Hugot-Cournez S., and Nault B. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol 100 (2005) 362-372
18. Degen L., Matzinger D., Merz M., Appel-Dingemanse S., Osborne S., Lüchinger S., Bertold R., Maecke H., and Beglinger C. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 15 (2001) 1745-1751
19. Tack J., Vos R., Janssens J., Salter J., Jauffret S., and Vandeplassche G. Influence of tegaserod on proximal gastric tone and on the perception of gastric distension. Aliment Pharmacol Ther 18 (2003) 1031-1037
20. Van Der Voort I.R., Schmidtmann M., Fach K., Wemer C., Andresen V., Wiedenmann B., Burghard P., Klapp B.F., and Moennikes H. Tegaserod improves gastric emptying and alters myocardial activity in dyspeptic patients. Gastroenterology 126 Suppl 2 (2004) A643
21. Nasr I., Attaluri A., Summers R., Rao S., and Hashmi S. Effect of tegaserod on antroduodenal and jejunal motility. Gastroenterology 130 Suppl 2 (2006) A743
22. Thumshirn M., Fruehauf H., Stutz B., Tougas G., Salter J., and Fried M. Clinical trial: effects of tegaserod on gastric motor and sensory function in patients with functional dyspepsia. Aliment Pharmacol Ther 26 (2007) 1399-1407. This paper demonstrates enhancement of meal-induced gastric relaxation by the 5-HT4 agonist tegaserod in functional dyspepsia.
23. Tack J., Delia T., Ligozio G., Sue S., Lefkowitz M., and Vandeplassche L. A phase II placebo controlled randomized trial with tegaserod (T) in functional dyspepsia (FD) with normal gastric emptying (NGE). Gastroenterology 122 (2002) A-20
24. Tougas G., Chen Y., Luo D., Salter J., D'Elia T., and Earnest D.L. Tegaserod improves gastric emptying in patients with gastroparesis and dyspeptic symptoms (abstract). Gastroenterology 124 (2003) A54
25. Vakil N., Laine L., Talley N.J., Zakko S., Tack J., Chey W.D., Kralstein J., Earnest D.L., Ligozio G., and Cohard-Radice M. Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. Am J Gastroenterol 103 (2008) 1906-1919. Report of two large phase 3 studies of tegaserod in functional dyspepsia. Although the studies show mixed efficacy results, it provides valuable information for future trials in the assessment of different endpoints and severity-based subgroups of patients.
26. Scarpellini E., and Tack J. Renzapride: a new drug for the treatment of irritable bowel syndrome. Expert Opin Investig Drugs 17 (2008) 1663-1670
27. Tack J., Middleton S.J., Horne M.C., Piessevaux H., Bloor J.S., Meyers N.L., and Palmer R.M.J. Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 23 (2006) 1655-1665
28. Meyers N.L., Palmer R.M.J., Wray H.A., Bloor J.R., and Wilding I.R. Effects of single oral doses of renzapride on gastrointestinal motility in fasted, healthy subjects (abstract). Gut 51 (2002) SIII A137
29. Mackie A.D., Ferrington C., Cowan S., Merrick M.V., Baird J.D., and Palmer K.R. The effects of renzapride, a novel prokinetic agent, in diabetic gastroparesis. Aliment Pharmacol Ther 5 (1991) 135-142
30. Meyers N.L., and Hickling R.I. The cardiovascular safety profile of renzapride, a novel treatment for irritable bowel syndrome. J Int Med Res 35 (2007) 848-866
31. Potet F., Bouyssou T., Escande D., and Baro' I. Gastrointestinal prokinetic drugs have different affinity for the human cardiac ether-à-gogo channel. J Pharm Exp Ther 299 (2001) 1007-1012
32. Kanaizumi T., Nakano H., Matsui Y., Ishikawa H., Shimizu R., Park S., and Kuriya N. Prokinetic effect of AS-4370 on gastric emptying in healthy adults. Eur J Clin Pharmacol 29 (1991) 670-675
33. Hallerbäck B.I., Bommelaer G., Bredberg E., Campbell M., Hellblom M., Lauritsen K., Wienbeck M., and Holmgren L.L. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment Pharmacol Ther 16 (2002) 959-967
34. Bouras E.P., Camilleri M., Burton D.D., Thomforde G., McKinzie S., and Zinsmeister A.R. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 120 (2001) 354-360
35. Camilleri M., Kerstens R., Rykx A., and Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 358 (2008) 2344-2354
36. Camilleri M., Vazquez-Roque M.I., Burton D., Ford T., McKinzie S., Zinsmeister A.R., and Druzgala P. Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil 19 (2007) 30-38
37. Beattie D.T., Armstrong S.R., Shaw J.P., Marquess D., Sandlund C., Smith J.A., Taylor J.A., and Humphrey P.P. The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol 378 (2008) 139-147
38. Iwanaga Y., Miyashita N., Saito T., Morikawa K., and Itoh Z. Gastroprokinetic effect of a new benzamide derivative itopride and its action mechanisms in conscious dogs. Jpn J Pharmacol 71 (1996) 129-137
39. Holtmann G., Talley N.J., Liebregts T., Adam B., and Parow C. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med 354 (2006) 832-840
40. Talley NJ, Tack J, Ptak T, Gupta R, Giguère M: F Itopride in functional dyspepsia: results of two Phase III multicenter, randomized, double-blind, placebo-controlled trials. Gut 2008; 57:740-6. Report of two large phase 3 studies with itopride in functional dyspepsia. Although the studies are negative, the paper offers insights on the potential impact of strict exclusion of heartburn in functional dyspepsia trials.
41. Choung R.S., Talley N.J., Peterson J., Camilleri M., Burton D., Harmsen W.S., and Zinsmeister A.R. A double-blind, randomized, placebo-controlled trial of itopride (100 and 200 mg three times daily) on gastric motor and sensory function in healthy volunteers. Neurogastro Motil 19 (2007) 180-187
42. Stevens J.E., Russo A., Maddox A.F., Rayner C.K., Phillips L., Talley N.J., Giguère M., Horowitz M., and Jones K.L. Effect of itopride on gastric emptying in longstanding diabetes mellitus. Neurogastroenterol Motil 20 (2008) 456-463
43. Tack J., and Peeters T. What comes after macrolides and other motilin stimulants?. Gut 49 (2001) 317-318
44. Cuomo R., Vandaele P., Coulie B., Peeters T., Depoortere I., Janssens J., and Tack J. Influence of motilin on gastric fundus tone and on meal-induced satiety in man: role of cholinergic pathways. Am J Gastroenterol 101 (2006) 804-811
45. McCallum R.W., Cynshi O., and Investigative Team. Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis-a randomized, multicentre, placebo-controlled study. Aliment Pharmacol Ther 26 (2007) 1121-1130
46. McCallum R.W., Cynshi O., and Investigative Team. Clinical trial: effect of mitemcinal, a motilin agonist, on gastrointestinal symptoms in patients with symptoms suggesting diabetic gastropathy: a randomized, multicentre, placebo-controlled study. Aliment Pharmacol Ther 26 (2007) 107-116. In this manuscript, post hoc exploration identifies subgroups of patients with diabetic gastropathy who may be more likely to respond to a macrolide type prokinetic drug.
47. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., and Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402 (1999) 656-660
48. Depoortere I., De Winter B., Thijs T., De Man J., Pelckmans P., and Peeters T. Comparison of the gastroprokinetic effects of ghrelin, GHRP-6 and motilin in rats in vivo and in vitro. Eur J Pharmacol 515 (2005) 160-168
49. Tack J., Depoortere I., Bisschops R., Delporte C., Coulie B., Meulemans A., Janssens J., and Peeters T. Influence of ghrelin on interdigestive gastrointestinal motility in humans. Gut 55 (2006) 327-333
50. Levin F., Edholm T., Schmidt P.T., Grybäck P., Jacobsson H., Degerblad M., Höybye C., Holst J.J., Rehfeld J.F., Hellström P.M., and Näslund E. Ghrelin stimulates gastric emptying and hunger in normal-weight humans. J Clin Endocrinol Metab 91 (2006) 3296-3302
51. Tack J., Depoortere I., Bisschops R., Verbeke K., Janssens J., and Peeters T. Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. Aliment Pharmacol Ther 22 (2005) 847-853. First paper to establish therapeutic potential for ghrelin in gastroparesis.
52. Murray C.D., Martin N.M., Patterson M., Taylor S.A., Ghatei M.A., Kamm M.A., Johnston C., Bloom S.R., and Emmanuel A.V. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut 54 (2005) 1693-1698
53. Ang D, Nicolai H, Vos R, Mimidis K, Akyuz F, Vanden Berghe P, Sifrim D, Depoortere I, Peeters T, Tack J: Influence of ghrelin on the gastric accommodation reflex and on meal-induced satiety in man. Neurogastroenterol Motil 2008, in press.
54. Lasseter K.C., Shaughnessy L., Cummings D., Pezzullo J.C., Wargin W., Gagnon R., Oliva J., and Kosutic G. Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol 48 (2008) 193-202
55. Miller L.S., Szych G.A., Kantor S.B., Bromer M.Q., Knight L.C., Maurer A.H., Fisher R.S., and Parkman H.P. Treatment of idiopathic gastroparesis with injection of botulinum toxin into the pyloric sphincter muscle. Am J Gastroenterol 97 (2002) 1653-1660
56. Arts J., van Gool S., Caenepeel P., Verbeke K., Janssens J., and Tack J. Influence of intrapyloric botulinum toxin injection on gastric emptying and meal-related symptoms in gastroparesis patients. Aliment Pharmacol Ther 24 (2006) 661-667
57. Arts J., Holvoet L., Caenepeel P., Bisschops R., Sifrim D., Verbeke K., Janssens J., and Tack J. Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis. Aliment Pharmacol Ther 26 (2007) 1251-1258. This paper, as well as the next one, confirms again the unreliability of uncontrolled trials in motility disorders such as gastroparesis.
58. Friedenberg F.K., Palit A., Parkman H.P., Hanlon A., and Nelson D.B. Botulinum toxin A for the treatment of delayed gastric emptying. Am J Gastroenterol 103 (2008) 416-423. This paper, as well as the previous one, confirms again the unreliability of uncontrolled trials in motility disorders such as gastroparesis.
59. Gilja O.H., Hausken T., Bang C.J., and Berstad A. Effect of glyceryl trinitrate on gastric accommodation and symptoms in functional dyspepsia. Dig Dis Sci 42 (1997) 2124-2131
60. Sarnelli G., Sifrim D., Janssens J., and Tack J. Influence of sildenafil on gastric sensorimotor function in humans. Am J Physiol Gastrointest Liver Physiol 287 (2004) G988-G992
61. Tack J., Broekaert D., Coulie B., Fischler B., and Janssens J. Influence of the selective serotonin re-uptake inhibitor, paroxetine, on gastric sensorimotor function in humans. Aliment Pharmacol Ther 17 (2003) 603-608
62. Tack J., Vanden Berghe P., Coulie B., and Janssens J. Sumatriptan is an agonist at 5-HT receptors on myenteric neurones in the guinea-pig gastric antrum. Neurogastroenterol Motil 19 (2007) 39-46
63. Tack J., Coulie B., Wilmer A., Andrioli A., and Janssens J. Influence of sumatriptan on gastric fundus tone and on the perception of gastric distension in man. Gut 46 (2000) 468-473
64. Sarnelli G., Janssens J., and Tack J. Effect of intranasal sumatriptan on gastric tone and sensitivity to distension. Dig Dis Sci 46 (2001) 1591-1595
65. Coleman N.S., Marciani L., Blackshaw E., Wright J., Parker M., Yano T., Yamazaki S., Chan P.Q., Wilde K., Gowland P.A., et al. Effect of a novel 5-HT3 receptor agonist MKC-733 on upper gastrointestinal motility in humans. Aliment Pharmacol Ther 18 (2003) 1039-1048
66. Van Oudenhove L., Kindt S., Vos R., Coulie B., and Tack J. Influence of buspirone on gastric sensorimotor function in man. Aliment Pharmacol Ther (2008) [Epub ahead of print]
67. 1A receptor stimulation on the proximal stomach in man.
68. Tack J, Van Elzen B, Tytgat G, Wajs E, Van Nueten L, De Ridder F, Boeckxstaens G: A placebo-controlled trial of the 5-HT1A agonist R-137696 on symptoms, visceral hypersensitivity and on impaired accommodation in functional dyspepsia. Neurogastroenterol Motil 2008, submitted for publication.
69. Thumshirn M., Camilleri M., Choi M.G., and Zinsmeister A.R. Modulation of gastric sensory and motor functions by nitrergic and alpha2-adrenergic agents in humans. Gastroenterology 116 (1999) 573-585
70. Doi Y., Murasaki O., Kaibara M., Uezono Y., Hayashi H., Yano K., and Taniyama K. Characterization of functional effect of Z-338, a novel gastroprokinetic agent, on the muscarinic M1, M2, and M3 receptors expressed in Xenopus oocytes. Eur J Pharmacol 505 (2004) 31-35
71. Tack J, Masclee A, Heading RC, Berstad A, Piessevaux H, Popiela T, Vandenberghe A, Kato H: A dose-ranging, placebo-controlled pilot trial of acotiamide in patients with functional dyspepsia. Neurogastroenterol Motil 2008, in press.
72. Seto K., Sasaki T., Katsunuma K., Kobayashi N., Tanaka K., and Tack J. Z-338, a novel gastroprokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats. Neurogastroenterol Motil 20 (2008) 1051-1059 Epub ahead of print
73. Talley N.J., Tack J., Kowalski D., Borton M.A., and Barve A. A novel acetylcholine esterase inhibitor acotiamide hydrochloride (ym443) in functional dyspepsia: efficacy in a randomized, double-blind, placebo-controlled dose ranging trial. Gastroenterology 4 Suppl 1 (2008) A-157 (abstract)